Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy

NCT02882477 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT02882477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02882477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy
Lead sponsor
Hadassah Medical Organization
Phase
Phase 2/3
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2018
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, gastroduodenal ulcer, iron metabolism disorders, optic atrophy, platelet dysfunction, sensorineural hearing loss